Tafro syndrome: Critical review for clinicians and pathologists

PAYDAŞ S.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.128, pp.88-95, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 128
  • Publication Date: 2018
  • Doi Number: 10.1016/j.critrevonc.2018.05.015
  • Journal Name: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.88-95
  • Keywords: TAFRO, Castleman disease, Anasarca, Fever, Reticulin fibrosis, Organomegaly, MULTICENTRIC CASTLEMAN-DISEASE, ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, KOJIMA DISEASE, CYCLOSPORINE-A, IMMUNE THROMBOCYTOPENIA, DIAGNOSTIC-CRITERIA, VARIANT, ANASARCA, TOCILIZUMAB, PATIENT
  • Çukurova University Affiliated: Yes

Abstract

TAFRO is an acrostic and includes thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R) and organomegaly (O) (Takai et al., 2013). TAFRO syndrome has been described firstly by Takai in Japanese patients. However TAFRO cases have been reported from US, Europe and other countries (Takai et al., 2010; Iwaki et al., 2016; Abdo et al., 2014). Three major and at least one minor criteria and exclusion of infectious, rheumatologic and neoplastic diseases are required for the diagnosis of TAFRO. In fact TAFRO must be thought in clinically undiagnosed and unsolved problemmatic cases.